The ecarin clotting time
(ECT) is a global test that reflects the activity of the coagulation cascade downstream from FII (15).
Ecarin clotting time
(ECT): Ecarin is a metalloproteinase that activates prothrombin independent of calcium, phospholipid, and Factor V.
Most cardiac surgical units are not equipped with an ecarin clotting time
point-of-care analyser (specific for bivalirudin) (11), although use of plasma modified ACT has been described (12).
The first diagnostic test, the Ecarin Clotting Time
("ECT") test, was developed to monitor the effect of Knoll's thrombin inhibitor PEG Hirudin.
The primary endpoint of the study is the degree of reversal of the anticoagulant effect of dabigatran achieved by 5 g idarucizumab within 4 hours measured by diluted thrombin time (dTT) and ecarin clotting time
Ecarin clotting time
(ECT) assays can be used to monitor DTI levels, including argatroban.
The authors are to be congratulated for their successful outcome and their detailed description of the modified ecarin clotting time
(ECT) used to monitor the anticoagulation.
Subsequent to the close of the third quarter, the Company announced the signing of an agreement with The Medicines Company (TMC) (Nasdaq/NM:MDCO), under which TMC will purchase Ecarin Clotting Time
(ECT) tests for the rapid evaluation of the anticoagulant effects of Angiomax(R) (bivalirudin), TMC's direct thrombin inhibitor.
Under the terms of the agreement, TMC will purchase Ecarin Clotting Time
(ECT) tests for the rapid evaluation of the anticoagulant effects of Angiomax(R)(bivalirudin), TMC's direct thrombin inhibitor.
The anticoagulant effect of dabigatran and its reversal were assessed using diluted thrombin time (Hemoclot DTI assay), thrombin time (TT), activated partial thromboplastin time (aPTT), ecarin clotting time
(ECT) and activated clotting time (ACT).
Patients are being enrolled in studies at several medical institutions including the Cleveland Clinic to demonstrate the utility of the Ecarin Clotting Time
test in a number of clinical settings including dialysis, PTCA and surgery.
CVDI's first collaboration with Knoll, developing an Ecarin Clotting Time
(ECT) test for Knoll's new thrombin inhibitor, PEG-Hirudin, resulted in a $2.